MARKET

ALLO

ALLO

Allogene Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

48.94
+0.78
+1.62%
Pre Market: 48.00 -0.94 -1.92% 06:25 06/02 EDT
OPEN
46.12
PREV CLOSE
48.16
HIGH
50.46
LOW
44.00
VOLUME
1.55M
TURNOVER
--
52 WEEK HIGH
55.00
52 WEEK LOW
17.43
MARKET CAP
6.13B
P/E (TTM)
-24.5720
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 16 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ALLO stock price target is 50.15 with a high estimate of 70.00 and a low estimate of 28.00.

EPS

ALLO News

More
Allogene Therapeutics Prices 11.7M Share Public Offering of Common Stock @$47/Share
Allogene Therapeutics, Inc. (NASDAQ: ALLO) announced the pricing of an underwritten public offering of 11,702,128 shares of its common stock at a price to the public of $47.00 per share.
Benzinga · 1h ago
Allogene Therapeutics launches $450M equity offering
Allogene Therapeutics (NASDAQ:ALLO) commences a $450M public offering of common stock. Underwriters' over-allotment is an additional $67.5M shares. Price,
seekingalpha · 18h ago
Why Allogene Therapeutics Is Trading Lower Today
Benzinga · 18h ago
Why Allogene Therapeutics Is Trading Lower Today
Allogene Therapeutics (NASDAQ: ALLO) shares were trading lower on Monday. The company announced it would commence a $450 million offering of its common stock. Raymond James also downgraded the stock from Outperform to Market Perform.
Benzinga · 19h ago
Oppenheimer Maintains Outperform on Allogene Therapeutics, Raises Price Target to $55
Oppenheimer maintains Allogene Therapeutics (NASDAQ:ALLO) with a Outperform and raises the price target from $50 to $55.
Benzinga · 19h ago
Raymond James Downgrades Allogene Therapeutics to Market Perform
Raymond James analyst Dane Leone downgrades Allogene Therapeutics (NASDAQ:ALLO) from Outperform to Market Perform.
Benzinga · 1d ago
Allogene Therapeutics Announces Commencement of Public Offering of Common Stock
GlobeNewswire · 1d ago
Cancer Summit Presses Toward Treatments in Covids Shadow
Bloomberg · 1d ago

Industry

Biotechnology & Medical Research
+0.07%
Pharmaceuticals & Medical Research
-0.77%

Hot Stocks

Symbol
Price
%Change

About ALLO

Allogene Therapeutics, Inc. is a clinical stage immuno-oncology company. The Company is focused on developing and commercializing of allogeneic T cell therapies for the treatment of cancer. It is involved in developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and T cell manufacturing technologies. Its T cell product candidates are designed to target and kill cancer cells. Its product candidate includes UCART19, ALLO-501, ALLO-715 and ALLO-647. The Company’s UCART19 is an allogeneic CAR T cell therapy that targets CD19. The Company’s ALLO-501 is an allogeneic anti-CD19 CAR T cell product candidate, which is designed for the treatment of patients with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL). The Company’s ALLO-715 targets B-cell maturation antigen (BCMA) for the treatment of patients with R/R multiple myeloma.
More

Webull offers kinds of Allogene Therapeutics Inc stock information, including NASDAQ:ALLO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALLO stock news, and many more online research tools to help you make informed decisions.